Barbara A. Conley
National Cancer Institute · 314 works · 11,251 citations · h-index 51
Top works
- Prognostic Factors in Colorectal Cancer
- National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network
- Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07
- Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials
- Perspectives on Comorbidity and Cancer in Older Patients: Approaches to Expand the Knowledge Base
- Interlaboratory Comparability Study of Cancer Gene Expression Analysis Using Oligonucleotide Microarrays
- Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers
- Criteria for the use of omics-based predictors in clinical trials
- Molecular Analysis for Therapy Choice: NCI MATCH
- Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
- Pharmacodynamics in cancer therapy.
- Detection of Prostate Cancer and Predicting Progression
- Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
- N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma
- Vascular Injury Induces Expression of Periostin
- Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial
- Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
- The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design